0.45
-0.012(-2.58%)
Currency In USD
Address
1001 North US HWY 1
Jupiter, FL 33477
United States of America
Phone
561 406 6154
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
January 18, 2022
| Name | Title | Pay | Year Born |
| Christer Rosen | Co-Founder, Chief Executive Officer & Chairman of the Board | 154,076 | 1952 |
| Alexander Rosen | Co-Founder & Chief Administrative Officer | 103,655 | 1991 |
| Marshall Hayward | Co-Founder, Chief Scientific Officer & Director | 107,800 | 1955 |
| Saleem Elmasri | Chief Financial Officer & Secretary | 127,006 | 1986 |
| Alison D. Silva | President, Chief Business Officer & Director | 138,544 | 1979 |
| Claes Wahlestedt | Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer | 0 | 1958 |
| Shaun Brothers | Co-Founder Member of Scientific Advisory Board & Consulting Vice President of Science Research | 0 | 1978 |
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.